Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paul Workman

Showing results (271-280 of 315) with videos related to

Pageof 32
Sort By:
Cancer Research|May 20, 2016
Second-Generation HSP90 Inhibitor Onalespib Blocks mRNA Splicing of Androgen Receptor Variant 7 in Prostate Cancer CellsRoberta Ferraldeschi, Jonathan Welti, Marissa V Powers, et al.
Scientific Reports|October 7, 2016
A fragment-based approach applied to a highly flexible target: Insights and challenges towards the inhibition of HSP70 isoformsAlan M Jones, Isaac M Westwood, James D Osborne, et al.
Cancer Research|March 3, 2007
In vitro biological characterization of a novel, synthetic diaryl pyrazole resorcinol class of heat shock protein 90 inhibitorsSwee Y Sharp, Kathy Boxall, Martin Rowlands, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 10, 2009
EGFRvIII deletion mutations in pediatric high-grade glioma and response to targeted therapy in pediatric glioma cell linesDorine A Bax, Nathalie Gaspar, Suzanne E Little, et al.
ACS Chemical Biology|July 2, 2025
Mediator Kinase Inhibitor Selectivity and Activity in Colorectal CancerMaria J Ortiz-Ruiz, Olajumoke Popoola, Konstantinos Mitsopoulos, et al.
Oncotarget|September 28, 2013
The discovery of potent ribosomal S6 kinase inhibitors by high-throughput screening and structure-guided drug designSylvain Couty, Isaac M Westwood, Andrew Kalusa, et al.
Molecular Cancer Therapeutics|December 31, 2010
Preclinical pharmacology, antitumor activity, and development of pharmacodynamic markers for the novel, potent AKT inhibitor CCT128930Timothy A Yap, Mike I Walton, Lisa-Jane K Hunter, et al.
Cancer Research|January 4, 2019
Correction: <i>In vitro</i> Biological Characterization of a Novel, Synthetic Diaryl Pyrazole Resorcinol Class of Heat Shock Protein 90 InhibitorsSwee Y Sharp, Kathy Boxall, Martin Rowlands, et al.
Journal of Medicinal Chemistry|June 23, 2010
Imidazo[4,5-b]pyridine derivatives as inhibitors of Aurora kinases: lead optimization studies toward the identification of an orally bioavailable preclinical development candidateVassilios Bavetsias, Jonathan M Large, Chongbo Sun, et al.
Journal of Medicinal Chemistry|January 12, 2026
Unhooking the Hook: Optimization of the Aurora A Targeting PROTAC <b>JB170</b> to <b>CCT400028</b>, an <i>In Vitro</i> Degrader Chemical ProbeJack A O'Hanlon, Katrin Gutsche, Juliane Elisabeth Müller, et al.
Pageof 32

Showing results (271-280 of 315) with videos related to

Sort By:
Pageof 32
Cancer Research|May 20, 2016
Second-Generation HSP90 Inhibitor Onalespib Blocks mRNA Splicing of Androgen Receptor Variant 7 in Prostate Cancer CellsRoberta Ferraldeschi, Jonathan Welti, Marissa V Powers, et al.
Scientific Reports|October 7, 2016
A fragment-based approach applied to a highly flexible target: Insights and challenges towards the inhibition of HSP70 isoformsAlan M Jones, Isaac M Westwood, James D Osborne, et al.
Cancer Research|March 3, 2007
In vitro biological characterization of a novel, synthetic diaryl pyrazole resorcinol class of heat shock protein 90 inhibitorsSwee Y Sharp, Kathy Boxall, Martin Rowlands, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 10, 2009
EGFRvIII deletion mutations in pediatric high-grade glioma and response to targeted therapy in pediatric glioma cell linesDorine A Bax, Nathalie Gaspar, Suzanne E Little, et al.
ACS Chemical Biology|July 2, 2025
Mediator Kinase Inhibitor Selectivity and Activity in Colorectal CancerMaria J Ortiz-Ruiz, Olajumoke Popoola, Konstantinos Mitsopoulos, et al.
Oncotarget|September 28, 2013
The discovery of potent ribosomal S6 kinase inhibitors by high-throughput screening and structure-guided drug designSylvain Couty, Isaac M Westwood, Andrew Kalusa, et al.
Molecular Cancer Therapeutics|December 31, 2010
Preclinical pharmacology, antitumor activity, and development of pharmacodynamic markers for the novel, potent AKT inhibitor CCT128930Timothy A Yap, Mike I Walton, Lisa-Jane K Hunter, et al.
Cancer Research|January 4, 2019
Correction: <i>In vitro</i> Biological Characterization of a Novel, Synthetic Diaryl Pyrazole Resorcinol Class of Heat Shock Protein 90 InhibitorsSwee Y Sharp, Kathy Boxall, Martin Rowlands, et al.
Journal of Medicinal Chemistry|June 23, 2010
Imidazo[4,5-b]pyridine derivatives as inhibitors of Aurora kinases: lead optimization studies toward the identification of an orally bioavailable preclinical development candidateVassilios Bavetsias, Jonathan M Large, Chongbo Sun, et al.
Journal of Medicinal Chemistry|January 12, 2026
Unhooking the Hook: Optimization of the Aurora A Targeting PROTAC <b>JB170</b> to <b>CCT400028</b>, an <i>In Vitro</i> Degrader Chemical ProbeJack A O'Hanlon, Katrin Gutsche, Juliane Elisabeth Müller, et al.
Pageof 32